Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature

Abstract Brentuximab Vedotin is an antibody – drug conjugate targeting CD 30. We report a case of severe cytokine release syndrome ( CRS ) after administration of the first dose of Brentuximab Vedotin in a 64‐yr‐old patient with relapsed systemic anaplastic large cell lymphoma (s ALCL ). To our knowledge, this is the first case of CRS to B rentuximab Vedotin described in the literature. However, CRS to Brentuximab Vedotin might be underestimated, as the drug has not been tested in large phase III trials yet.